tiprankstipranks
Advertisement
Advertisement

CGTX Stock Latest News

Cognition Therapeutics gets FDA feedback on zervimesine study
The FlyCognition Therapeutics gets FDA feedback on zervimesine study
6d ago
CGTX
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor
PremiumCompany Announcements
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor
12d ago
8K
CGTX
Cognition Therapeutics gets notice of allowance from USPTO for zervimesine
PremiumThe Fly
Cognition Therapeutics gets notice of allowance from USPTO for zervimesine
14d ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial
PremiumCompany Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial
26d ago
8K
CGTX
Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
PremiumRatings
Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
1M ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
PremiumCompany AnnouncementsCognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
1M ago
8K
CGTX
Cognition Therapeutics conducts zervimesine meeting with FDA
Premium
The Fly
Cognition Therapeutics conducts zervimesine meeting with FDA
1M ago
CGTX
Ram Selvaraju Reiterates Buy on Cognition Amid Clinical Progress and Regulatory Milestones, Keeps 12-Month Price Target Unchanged at $3
Premium
Ratings
Ram Selvaraju Reiterates Buy on Cognition Amid Clinical Progress and Regulatory Milestones, Keeps 12-Month Price Target Unchanged at $3
2M ago
CGTX
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
PremiumThe Fly
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
2M ago
CGTX
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
PremiumRatings
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
3M ago
CGTX
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
PremiumCompany Announcements
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
3M ago
8K
CGTX
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
PremiumThe Fly
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
3M ago
CGTX
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
PremiumRatingsCognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
4M ago
CGTX
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
4M ago
8K
CGTX
Cognition Therapeutics announces plans to advance development of zervimesine
Premium
The Fly
Cognition Therapeutics announces plans to advance development of zervimesine
4M ago
CGTX
Cognition Therapeutics extends duration of EAP for zervimesine
PremiumThe Fly
Cognition Therapeutics extends duration of EAP for zervimesine
5M ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
PremiumCompany Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
5M ago
8K
CGTX
Cognition Therapeutics completes Type C meeting with FDA for zervimesine
PremiumThe Fly
Cognition Therapeutics completes Type C meeting with FDA for zervimesine
5M ago
CGTX
Cognition publishes Phase 2 results on Zervimesine
PremiumThe Fly
Cognition publishes Phase 2 results on Zervimesine
6M ago
CGTX
Cognition Therapeutics Launches New $75M ATM Offering
PremiumCompany AnnouncementsCognition Therapeutics Launches New $75M ATM Offering
6M ago
8K
CGTX
Cognition Therapeutics files $300M mixed securities shelf
Premium
The Fly
Cognition Therapeutics files $300M mixed securities shelf
6M ago
CGTX
Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
Premium
Ratings
Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
7M ago
CGTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >